Knee Osteoarthritis
Conditions
Keywords
SM04690, osteoarthritis, Samumed, lorecivivint, DYRK1a, CLK2
Brief summary
The primary purpose of this phase 2, placebo-controlled, double-blind, parallel group study was to provide an initial safety evaluation of two intra-articular (IA) injections of SM04690 (each at the dose of 0.07mg per 2mL injection) approximately six months apart into the target knee of moderately to severely symptomatic osteoarthritis (OA) subjects. Subjects who completed this 52-week long study were invited to enter the extension phase for an additional 52 weeks of treatment.
Detailed description
Study SM04690-OA-06 was a multicenter, randomized, double-blind, placebo-controlled, parallel group study of a single concentration of 0.07 mg SM04690 per 2 mL injection injected into the target knee joint of moderately to severely symptomatic OA subjects at Day 1 and Week 24 (Phase A). Subjects who completed Phase A were eligible to enter the single-blind extension phase, Phase B, for an additional 52 weeks of study treatment, receiving the randomized Phase A treatment at Week 52 and again at Week 76. The study was primarily designed to assess the safety and tolerability of repeated SM04690 injections, focusing not only on AEs but also several assessments of bone density in the knee.
Interventions
DRUGPlacebo
Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
DRUGSM04690
Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Sponsors
Biosplice Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females between 40 and 80 years of age, inclusive, in general good health 2. Ambulatory 3. Diagnosis of femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria at Screening Visit 1 (clinical AND radiographic criteria); OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis) 4. Pain compatible with OA of the knee(s) for at least 26 weeks prior to Screening Visit 1 5. Primary source of pain throughout the body is due to OA in the target knee 6. Daily OA knee pain diary average NRS intensity score ≥ 4 and ≤ 8 in the target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1 7. Pain NRS scores recorded for the target knee on at least 4 out of the 7 days immediately preceding Day 1 8. Daily OA knee pain diary average NRS intensity score \< 4 in the non-target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1 9. Pain NRS scores recorded for the non-target knee on at least 4 out of the 7 days immediately preceding Day 1 10. WOMAC pain subscore of 20-40 (out of 50) and WOMAC physical function subscore of 68-136 (out of 170) for the target knee at baseline, regardless of if the subject is on symptomatic oral treatment (baseline questionnaire completed during the screening period prior to randomization) 11. Widespread Pain Index (WPI) score of ≤ 4 and a Symptom Severity Question 2 (SSQ2) score of ≤ 2 at Screening Visit 1 12. Willingness to use an electronic diary on a daily basis in the evening for the screening period and 104-week study duration 13. Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, benzodiazepine, methaqualone, and tricyclic antidepressants, except if any such drugs are clinically indicated and allowed by the protocol, at Screening Visit 1. 14. Subjects with depression or anxiety must be clinically stable for 12 weeks prior to Screening Visit 1 in the opinion of the Investigator and, if on treatment for depression or anxiety, be on 12 weeks of stable therapy 15. Full understanding of the requirements of the study and willingness to comply with all study visits and assessments 16. Subjects must have read and understood the Informed Consent Form (ICF), and must have signed and dated it prior to any study-related procedure being performed 17. Subject's Screening Visit 1 visit must occur while enrollment into the study is open 18. Subject is able to have a Screening Visit 2 qCT image acquired that does not require a re-scan as determined by the central imaging vendor
Exclusion criteria
1. Pregnant and breastfeeding women, and women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) and have a positive or indeterminate pregnancy result at Screening Visit 2 or Day 1 2. Women who are not post-menopausal or permanently surgically sterile, who are sexually active, and who are not willing to use birth control (as outlined in Section 5.3.1) during the study period 3. Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized or who are not using birth control as outlined in Section 5.3.1 4. Body mass index (BMI) \> 35 5. Partial or complete joint replacement in either knee 6. Currently requires: 1. regular use (in the opinion of the Investigator) of ambulatory assistive devices (e.g., wheelchair, parallel bars, walker, canes, or crutches), or 2. use of a lower extremity prosthesis, and/or a structural knee brace (i.e., a knee brace that contains hardware) 7. Radiographic disease Stage 0, 1, or 4 in the target knee at Screening Visit 1 according to the Kellgren-Lawrence grading of knee OA as assessed by independent central readers 8. Previous enrollment in a Samumed clinical trial investigating SM04690 9. Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Screening Visit 1 10. Any bone fracture(s) within 26 weeks prior to Screening Visit 1 11. Any surgery scheduled during the study period. Non-surgical invasive procedures conducted for a diagnostic or therapeutic purpose scheduled during the study period are not prohibited.(refer to section 7.6) 12. Significant and clinically evident misalignment of either knee that would impact subject function, as determined by the Investigator 13. History of malignancy within the last 5 years; however, subjects with prior history of in situ basal or squamous cell skin cancer are eligible if completely excised. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to Screening Visit 1 14. Clinically significant abnormal screening hematology values, blood chemistry values, or urinalysis values as determined by the Investigator 15. Any condition, including laboratory findings not included in the Screening Visit 2 laboratory tests and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation 16. Comorbid conditions that could affect study endpoint assessments of the target knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia 17. Other conditions that, in the opinion of the Investigator, could affect study endpoint assessments of either knee, including, but not limited to, peripheral neuropathy (e.g., diabetic neuropathy), symptomatic hip osteoarthritis, symptomatic degenerative disc disease, and patellofemoral syndrome 18. History of mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder 19. Participation in a clinical research trial that included the receipt of an investigational product (IP) or any experimental therapeutic procedure within 26 weeks prior to Screening Visit 1, or planned participation in any such trial 20. Treatment of the target knee with intra-articular glucocorticoids (e.g., methylprednisolone) within 12 weeks prior to Screening Visit 1 21. Any intra-articular injection into the target knee with a therapeutic aim including, but not limited to, viscosupplementation (e.g., hyaluronic acid), platelet-rich plasma (PRP), and stem cell therapies within 24 weeks prior to Screening Visit 1; treatment of the target knee with intra-articular glucocorticoids greater than 12 weeks prior to Screening Visit 1 is allowed 22. Treatment with systemic (oral, intramuscular, or intravenous) glucocorticoids greater than 10 mg prednisone or the equivalent per day within 4 weeks prior to Screening Visit 1 23. Effusion of the target knee clinically requiring aspiration within 12 weeks prior to Screening Visit 1 24. Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to Screening Visit 1 (refer to Appendix 1) 25. Any known active infections, including urinary tract infection, upper respiratory tract infection, sinusitis, suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV) at Day 1 26. Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of centrally acting analgesics (e.g., duloxetine) (refer to Appendix 1) within 12 weeks prior to Screening Visit 1 27. Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of anticonvulsants (not listed in Appendix 1) within 12 weeks prior to Screening Visit 1, unless used for seizure or migraine prophylaxis 28. Subjects requiring the usage of opioids \>1x per week within 12 weeks prior to Screening Visit 1 29. Topical local anesthetic agents (gels, creams, or patches such as the Lidoderm patch) used for the treatment of knee OA within 7 days of Screening Visit 1 30. Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy in the opinion of the Investigator. In addition, subjects with an HbA1c \>9 at Screening Visit 2 will be excluded. 31. If on NSAIDs for the treatment of OA pain, subjects who have not maintained a stable regimen in the opinion of the Investigator at Screening Visit 1 32. Any contraindications for performing DXA scans of the hips or spine including but not limited to: 1. other radiological investigations using contrast media or radionuclides within 7 days of Screening Visit 2 2. weight that precludes scanning at these sites 33. Subjects who have had a single or bilateral hip replacement 34. Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment 35. Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at any investigative site, or are directly affiliated with the study at any investigative site 36. Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study, or who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of said employees responsible for the conduct of the study 37. Subject has non-evaluable DXA scans of the hips or spine (i.e., pins, screws, any surgical implant, fracture, or severe degenerative changes in the region of interest), as assessed by the central imaging vendor at the time of screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | Baseline and Week 52 | Evaluate change in total bone mineral density (BMD) from baseline in the treated knee compared to placebo by quantitative computed tomography (qCT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | Baseline and Weeks 12 | Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Vehicle Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
Placebo: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.) | 50 |
| 0.07 mg SM04690 Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
SM04690: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.) | 51 |
| Total | 101 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Phase A | Lost to Follow-up | 2 | 3 |
| Phase A | Withdrawal by Subject | 10 | 9 |
| Phase B | Lost to Follow-up | 0 | 1 |
| Phase B | Site Closure | 4 | 0 |
| Phase B | Subject Non-Compliance | 1 | 0 |
| Phase B | Withdrawal by Subject | 3 | 3 |
Baseline characteristics
| Characteristic | Vehicle | 0.07 mg SM04690 | Total |
|---|---|---|---|
| Age, Continuous | 60.5 years STANDARD_DEVIATION 9.8 | 61.3 years STANDARD_DEVIATION 8.4 | 60.9 years STANDARD_DEVIATION 9.1 |
| Body Mass Index | 27.93 kg/m^2 STANDARD_DEVIATION 4.12 | 29.30 kg/m^2 STANDARD_DEVIATION 3.02 | 28.63 kg/m^2 STANDARD_DEVIATION 3.65 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 14 Participants | 13 Participants | 27 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 36 Participants | 38 Participants | 74 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Kellgren-Lawrence Grade Grade 2 | 31 Participants | 22 Participants | 53 Participants |
| Kellgren-Lawrence Grade Grade 3 | 19 Participants | 29 Participants | 48 Participants |
| Medial Joint Space Width | 3.193 mm STANDARD_DEVIATION 1.348 | 3.119 mm STANDARD_DEVIATION 1.216 | 3.156 mm STANDARD_DEVIATION 1.277 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 8 Participants | 9 Participants | 17 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 41 Participants | 40 Participants | 81 Participants |
| Sex: Female, Male Female | 34 Participants | 26 Participants | 60 Participants |
| Sex: Female, Male Male | 16 Participants | 25 Participants | 41 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 51 | 0 / 50 |
| other Total, other adverse events | 11 / 51 | 14 / 50 |
| serious Total, serious adverse events | 2 / 51 | 2 / 50 |
Outcome results
Primary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total bone mineral density (BMD) from baseline in the treated knee compared to placebo by quantitative computed tomography (qCT)
Time frame: Baseline and Week 52
Population: Full Analysis Set includes all subjects who received at least one study injection in Phase A. Subjects' observed data were analyzed as randomized for the FAS without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -0.47 mg/cm^3 | Standard Deviation 8.21 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -3.32 mg/cm^3 | Standard Deviation 10 |
95% CI: [-7.19, 1.58]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT
Time frame: Baseline and Weeks 12
Population: Full Analysis Set includes all subjects who received at least one study injection in Phase A. Subjects' observed data were analyzed as randomized for the FAS without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -0.38 mg/cm^3 | Standard Deviation 7.89 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -0.34 mg/cm^3 | Standard Deviation 7.28 |
95% CI: [-3.24, 3.24]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT
Time frame: Baseline and Week 24
Population: Full Analysis Set includes all subjects who received at least one study injection in Phase A. Subjects' observed data were analyzed as randomized for the FAS without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | 1.34 mg/cm^3 | Standard Deviation 7.77 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -0.76 mg/cm^3 | Standard Deviation 8.81 |
95% CI: [-5.84, 1.65]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT
Time frame: Baseline and Week 36
Population: Full Analysis Set includes all subjects who received at least one study injection in Phase A. Subjects' observed data were analyzed as randomized for the FAS without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -1.82 mg/cm^3 | Standard Deviation 8.47 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -2.06 mg/cm^3 | Standard Deviation 7.18 |
95% CI: [-4.05, 3.54]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT
Time frame: Baseline and Week 76
Population: Full Analysis Set (FASB) includes all subjects who received at least one study injection in Phase B. Subjects' observed data were analyzed as randomized for the FASB without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -2.13 mg/cm^3 | Standard Deviation 8.94 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -5.61 mg/cm^3 | Standard Deviation 10.67 |
95% CI: [-8.64, 2.23]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT
Time frame: Baseline and Week 88
Population: Full Analysis Set (FASB) includes all subjects who received at least one study injection in Phase B. Subjects' observed data were analyzed as randomized for the FASB without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -2.59 mg/cm^3 | Standard Deviation 10.52 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -5.14 mg/cm^3 | Standard Deviation 11.59 |
95% CI: [-8.75, 4.03]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total bone mineral density (BMD) from baseline in the treated knee compared to placebo by quantitative computed tomography (qCT)
Time frame: Baseline and Week 64
Population: Full Analysis Set (FASB) includes all subjects who received at least one study injection in Phase B. Subjects' observed data were analyzed as randomized for the FASB without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -4.56 mg/cm^3 | Standard Deviation 9.84 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -3.76 mg/cm^3 | Standard Deviation 9.94 |
95% CI: [-4.64, 6.23]
Secondary
Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT
Evaluate change in total BMD from baseline in the treated knee compared to placebo by qCT
Time frame: Baseline and Week 104
Population: Full Analysis Set (FASB) includes all subjects who received at least one study injection in Phase B. Subjects' observed data were analyzed as randomized for the FASB without imputation.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vehicle | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -2.95 mg/cm^3 | Standard Deviation 13.21 |
| 0.07 mg SM04690 | Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT | -7.08 mg/cm^3 | Standard Deviation 12.34 |
95% CI: [-11.21, 3.11]